<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Treatment of endemic Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CPM) and intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (IT MTX) can cure 50% of patients </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, induction therapy with CPM and IT MTX was followed by consolidation chemotherapy adapted for stage, clinical response, and abdominal ultrasound findings </plain></SENT>
<SENT sid="2" pm="."><plain>One hundred and twenty-nine consecutive patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, 77 male and 52 female with a median age of 7.9 years, were treated in mission hospitals in Cameroon </plain></SENT>
<SENT sid="3" pm="."><plain>The diagnosis rested on fine-needle aspirate (79%), biopsy, bone marrow, cerebrospinal fluid, abdominal ultrasound, and clinical examination </plain></SENT>
<SENT sid="4" pm="."><plain>Six percent had St Jude stage I, 13% stage II, 72% stage III, and 12% stage IV disease </plain></SENT>
<SENT sid="5" pm="."><plain>The abdomen (76%) and face (50%) were mainly involved </plain></SENT>
<SENT sid="6" pm="."><plain>Induction chemotherapy was CPM 40 mg/kg and IT MTX 12.5 mg and IT <z:chebi fb="2" ids="17650">hydrocortisone</z:chebi> 12.5 mg on days 1, 8, and 15 </plain></SENT>
<SENT sid="7" pm="."><plain>Stage I and II patients received CPM 60 mg/kg on day 29, and stage III patients CPM 60 mg/kg on days 29 and 43 if in remission on day 28 </plain></SENT>
<SENT sid="8" pm="."><plain>Stage IV patients and patients not in remission received CPM 60 mg/kg on days 29, 43, and 57 and 1.0 g/m(2) MTX intravenous (IV) and <z:chebi fb="0" ids="28445">vincristine</z:chebi> 1.5 mg/m(2) IV on day 29 </plain></SENT>
<SENT sid="9" pm="."><plain>Event-free survival (EFS) at mean 365 days was 61% (n = 79) and 100% in stage I, 85% in stage II, 60% in stage III, and 27% in stage IV patients </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0011420'>Deaths</z:hpo> (n = 24) were disease or treatment related and 26 patients relapsed (mean 135 days) </plain></SENT>
<SENT sid="11" pm="."><plain>Risk-adapted treatment achieved 61% 1-year EFS </plain></SENT>
</text></document>